Blood-based ATN (Aβ42/40/pTau181/NfL) Profile: Key Characteristics of Over 17,000 Unique Patient Results

Though Alzheimer’s Disease (AD) accounts for most dementia cases, up to 40% of patients may have another type of dementia.
Blood-based biomarkers (BBMs) for AD are now readily available, but how these markers are being employed in real-world clinical settings has not been extensively explored.
To assist in guiding clinical investigation, four assays were combined to create the ATN Profile.

Authors:

Managing Your Health